Related Experiment Video
Updated: Aug 6, 2026

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Nanoplastics forming micro-sized agglomerates and exacerbating neurotoxicity in Alzheimer's disease
Yiteng Xia1, Karl W K Tsim2, Wen-Xiong Wang1
1School of Energy and Environment, City University of Hong Kong, Kowloon, Hong Kong, China; Research Centre for the Oceans and Human Health, City University of Hong Kong Shenzhen Research Institute, Shenzhen 518057, China.
Abstract:
Micro/nanoplastics are quietly infiltrating human bodies through dietary intake, water consumption, and dermal exposure. Here, we assessed the interaction of nanoplastics (NPs) with β-amyloid (Aβ), helping to understand the likely mechanisms of NPs accumulation in brain and potential impacts on Alzheimer's disease (AD). SH-SY5Y cells served as an in vitro model of AD and were treated with fluorescently labeled NPs (NPf). In in vivo study, 5XFAD mice were fed with environmentally relevant doses of NPf for two weeks, and mouse behavior was analyzed by open field test. Brain tissue sections combined with confocal microscopy enabled the quantification and spatial localization of NPf in the brain. NPs aggregated with Aβ fibers and formed micrometer-sized agglomerates. In AD cell models, these agglomerates increased the intracellular NPs accumulation, reactive oxygen species formation and ethoxyresorufin-O-deethylase activity, ultimately inhibiting neurite outgrowth and causing cell death. In the AD mice, NPs exposure worsened the mice disease-related behaviors (e.g., reduced movement distance and speed) and resulted in larger NPs agglomerates and highly co-localization with Aβ in brain, consistent with the in vitro results. This study provided important data on NPs interaction with Aβ fiber from ex vivo to in vivo models, helping to understand the mechanisms of NPs accumulation in the brain.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Treatment

